JNJ

187.01

-0.37%↓

ABT

124.76

+1.17%↑

TMO

565.5

+1.94%↑

ISRG

536.71

+0.94%↑

DHR

214.8

+0.69%↑

JNJ

187.01

-0.37%↓

ABT

124.76

+1.17%↑

TMO

565.5

+1.94%↑

ISRG

536.71

+0.94%↑

DHR

214.8

+0.69%↑

JNJ

187.01

-0.37%↓

ABT

124.76

+1.17%↑

TMO

565.5

+1.94%↑

ISRG

536.71

+0.94%↑

DHR

214.8

+0.69%↑

JNJ

187.01

-0.37%↓

ABT

124.76

+1.17%↑

TMO

565.5

+1.94%↑

ISRG

536.71

+0.94%↑

DHR

214.8

+0.69%↑

JNJ

187.01

-0.37%↓

ABT

124.76

+1.17%↑

TMO

565.5

+1.94%↑

ISRG

536.71

+0.94%↑

DHR

214.8

+0.69%↑

Search

IQVIA Holdings Inc

Open

SectorHealthcare

215.41 2.45

Overview

Share price change

24h

Current

Min

209.08

Max

215.77

Key metrics

By Trading Economics

Income

17M

266M

Sales

188M

4B

P/E

Sector Avg

31.928

37.003

Profit margin

6.622

Employees

90,000

EBITDA

28M

781M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+9.63% upside

Market Stats

By TradingEconomics

Market Cap

10B

37B

Previous open

212.96

Previous close

215.41

News Sentiment

By Acuity

50%

50%

156 / 373 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

IQVIA Holdings Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Nov 2025, 21:44 UTC

Earnings

Vertex Pharmaceuticals Revenue Climbs on Demand for Cystic Fibrosis Drugs

3 Nov 2025, 23:44 UTC

Market Talk

Nikkei May Rise on Weaker Yen, Hopes for Govt Econ Steps -- Market Talk

3 Nov 2025, 23:34 UTC

Market Talk

Gold Edges Lower Amid Lingering Worry Over China's Ending of Tax Incentive -- Market Talk

3 Nov 2025, 23:28 UTC

Earnings

Palantir Revenue Hits Another Record as Defense Work Booms -- 2nd Update

3 Nov 2025, 23:24 UTC

Earnings

Correct: Grab Holdings Sees FY2025 Adj Ebitda $490M-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 Nov 2025, 23:14 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

3 Nov 2025, 23:14 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Deterra's Next CEO Might Bring New Approach to Deals -- Market Talk

3 Nov 2025, 23:12 UTC

Earnings

Grab Holdings Sees FY2025 Adj Ebitda $490-$500.0M, Higher Than $460M-$480M Projected in 2Q >GRAB

3 Nov 2025, 23:09 UTC

Earnings

Grab Holdings 3Q 2Q Adj EBITDA $136.0M Vs. $90.0M>GRAB

3 Nov 2025, 23:09 UTC

Earnings

Grab Holdings 3Q Net $17.0M Vs. Net $15.0M >GRAB

3 Nov 2025, 23:09 UTC

Earnings

Grab Holdings 3Q Rev $873.0M Vs. $716.0M >GRAB

3 Nov 2025, 23:06 UTC

Market Talk
Earnings

Palantir Execs Forecast Future of U.S. Workers In AI World -- Market Talk

3 Nov 2025, 22:36 UTC

Market Talk
Earnings

Palantir's U.S. Commercial Business Booms as It Expands AI -- Market Talk

3 Nov 2025, 22:31 UTC

Earnings

Franco-Nevada 3Q EPS $1.49 >FNV

3 Nov 2025, 22:31 UTC

Earnings

Franco-Nevada 3Q Rev $487.7M >FNV

3 Nov 2025, 22:24 UTC

Market Talk

Xero Bulls Expect Improving U.S. Momentum in 1H -- Market Talk

3 Nov 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

Starbucks Agrees to Sell Stake in China Business -- WSJ

3 Nov 2025, 21:59 UTC

Market Talk

RBA Set To Keep Rates On Hold; Remain Data Dependent -- Market Talk

3 Nov 2025, 21:54 UTC

Market Talk
Earnings

Westpac's Tech Challenge Keeps Jefferies Cautious -- Market Talk

3 Nov 2025, 21:54 UTC

Market Talk
Earnings

Global Equities Roundup: Market Talk

3 Nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Nov 2025, 21:49 UTC

Earnings

Palantir Revenue Hits Another Record as Defense Work Booms -- Update

3 Nov 2025, 21:40 UTC

Earnings

Barry Diller's IAC Inks AI Deal With Microsoft. That Isn't Why the Stock Is Sliding. -- Barrons.com

3 Nov 2025, 21:31 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in October -- Market Talk

3 Nov 2025, 21:19 UTC

Earnings

Palantir Revenue Hits Another Record as Defense Work Booms -- WSJ

3 Nov 2025, 21:11 UTC

Acquisitions, Mergers, Takeovers

Pfizer Reports Earnings Tuesday. Management Has Big Questions to Answer. -- Barrons.com

3 Nov 2025, 21:11 UTC

Earnings

Diamondback Energy: Increasing Full Yr Oil Production Guidance to 495-498 MBO/d and Increasing Annual BOE Guidance to 910-920 MBOE/d >FANG

3 Nov 2025, 21:07 UTC

Earnings

Palantir Technologies: Raising 2025 U.S. Comml Rev Guidance to in Excess of $1.433B, Representing a Growth Rate of at Least 104% >PLTR

3 Nov 2025, 21:05 UTC

Earnings

Vertex Pharmaceutic Sees 2025 Rev $11.9B-$12B >VRTX

3 Nov 2025, 21:05 UTC

Earnings

Palantir Technologies 3Q Net $475.6M >PLTR

Peer Comparison

Price change

IQVIA Holdings Inc Forecast

Price Target

By TipRanks

9.63% upside

12 Months Forecast

Average 237.31 USD  9.63%

High 265 USD

Low 200 USD

Based on 15 Wall Street analysts offering 12 month price targets forIQVIA Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

150.68 / 153.45Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

156 / 373 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat